Crescendo Bioscience Closes on $28M
Crescendo Bioscience, a molecular diagnostics company, has raised $28 Million in a Series D round led by Skyline Ventures and Safeguard Scientifics Inc. Existing investors Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers, and aeris CAPITAL also participated. Crescendo Bioscience is focused on developing and commercializing quantitative blood tests for rheumatoid arthritis and other auto-immune diseases.
3 January 2013•5 mins read
